Study finds previously unidentified genetic mutation in a small protein provides significant protection against Parkinson’s disease

As Blue­print Med­i­cines braces it­self for a fu­ture with­out a ma­jor Roche col­lab­o­ra­tion, the Mass­a­chu­setts biotech is pulling its RET in­hibitor from cer­tain mar­kets and

It’s a clas­sic bio­phar­ma sto­ry. In Jan­u­ary, David Khougaz­ian bumped in­to Flag­ship Pi­o­neer­ing founder Noubar Afeyan at the JP Mor­gan health­care con­fer­ence. They caught up,